Loading...

Penichet Manuel

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMicrobiology Immunology & Molecular Genetics
Address10833 Le Conte Ave.
BOX 951782 54-117 CHS
Los Angeles CA 90095
Phone(310) 206-5126
vCardDownload vCard
    Other Positions
    TitleProfessor


    Collapse Research 
    Collapse Research Activities and Funding
    A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL
    NIH/NCI R01CA196266Jan 1, 2016 - Dec 31, 2020
    Role: Principal Investigator
    (PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
    NIH/NCI R21CA193953May 1, 2015 - Apr 30, 2017
    Role: Principal Investigator
    A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
    NIH/NCI R01CA181115Sep 1, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity
    NIH/NCI R01CA136841Aug 5, 2010 - May 31, 2015
    Role: Principal Investigator
    Development of an anti-PSA IgE to treat prostate cancer
    NIH/NCI R41CA137881May 1, 2009 - Jul 31, 2010
    Role: Co-Principal Investigator
    Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
    NIH/NCI R01CA107023Dec 20, 2004 - Nov 30, 2010
    Role: Principal Investigator
    Universal Vectors for the Therapy of Cancer
    NIH/NCI K01CA086915Apr 1, 2001 - Mar 31, 2007
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Leoh LS, Kim YK, Candelaria PV, Martínez-Maza O, Daniels-Wells TR, Penichet M. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol. 2018 May 15; 200(10):3485-3494. PMID: 29654211.
      View in: PubMed
    2. Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet M, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF. Virus-like particle display of HER2 induces potent anti-cancer responses. Oncoimmunology. 2018; 7(3):e1408749. PMID: 29399414.
      View in: PubMed
    3. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet M. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2017; 8:1751. PMID: 29379493.
      View in: PubMed
    4. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet M. Corrigendum to "Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1" [Mol. Immunol. 67 (2015) 407-415]. Mol Immunol. 2016 12; 80:101. PMID: 27838011.
      View in: PubMed
    5. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet M, Jung ME, Gera J, Lichtenstein A. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Res. 2016 10 01; 76(19):5822-5831. PMID: 27530328.
      View in: PubMed
    6. Daniels-Wells TR, Penichet M. Transferrin receptor 1: a target for antibody-mediated cancer therapy. Immunotherapy. 2016 09; 8(9):991-4. PMID: 27373880.
      View in: PubMed
    7. Koru-Sengul T, Santander AM, Miao F, Sanchez LG, Jorda M, Glück S, Ince TA, Nadji M, Chen Z, Penichet M, Cleary MP, Torroella-Kouri M. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Res Treat. 2016 07; 158(1):113-26. PMID: 27283835.
      View in: PubMed
    8. Daniels-Wells TR, Widney DP, Leoh LS, Martínez-Maza O, Penichet M. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. J Immunother. 2015 Oct; 38(8):307-10. PMID: 26325374; PMCID: PMC4592199 [Available on 10/01/16].
    9. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet M. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol. 2015 Oct; 67(2 Pt B):407-15. PMID: 26232328; PMCID: PMC4636009 [Available on 10/01/16].
    10. Cornford EM, Hyman S, Cornford ME, Chytrova G, Rhee J, Suzuki T, Yamagata T, Yamakawa K, Penichet M, Pardridge WM. Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes. J Drug Target. 2016; 24(1):58-67. PMID: 26133964.
      View in: PubMed
    11. Leoh LS, Daniels-Wells TR, Penichet M. IgE immunotherapy against cancer. Curr Top Microbiol Immunol. 2015; 388:109-49. PMID: 25553797; PMCID: PMC4452505.
    12. De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet M, Iezzi M, Cavallo F, Nanni P, Lollini PL. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 2014 Jan 23; 16(1):R10. PMID: 24451168; PMCID: PMC3979148.
    13. Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet M, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014 Apr; 13(4):902-15. PMID: 24448822; PMCID: PMC4034757.
    14. Leoh LS, Morizono K, Kershaw KM, Chen IS, Penichet M, Daniels-Wells TR. Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med. 2014 Jan-Feb; 16(1-2):11-27. PMID: 24436117; PMCID: PMC4051223.
    15. Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet M, Martinez-Maza O. Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. PLoS One. 2013; 8(8):e72414. PMID: 23936541; PMCID: PMC3732224.
    16. Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet M, Ljubimova JY. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release. 2013 Nov 10; 171(3):322-9. PMID: 23770212; PMCID: PMC3971991.
    17. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet M. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer. 2013 Apr 17; 13:195. PMID: 23594731; PMCID: PMC3651304.
    18. VanderWall K, Daniels-Wells TR, Penichet M, Lichtenstein A. Iron in multiple myeloma. Crit Rev Oncog. 2013; 18(5):449-61. PMID: 23879589; PMCID: PMC3741338.
    19. Daniels-Wells TR, Helguera G, Rodríguez JA, Leoh LS, Erb MA, Diamante G, Casero D, Pellegrini M, Martínez-Maza O, Penichet M. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro. 2013 Feb; 27(1):220-31. PMID: 23085102; PMCID: PMC3513587.
    20. Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res Treat. 2012 Dec; 136(3):647-58. PMID: 23065001.
      View in: PubMed
    21. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):155-63. PMID: 22440007; PMCID: PMC3799862.
    22. Helguera G, Jemielity S, Abraham J, Cordo SM, Martinez MG, Rodríguez JA, Bregni C, Wang JJ, Farzan M, Penichet M, Candurra NA, Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses. J Virol. 2012 Apr; 86(7):4024-8. PMID: 22278244; PMCID: PMC3302512.
    23. Daniels TR, Martínez-Maza O, Penichet M. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother. 2012 Sep; 61(9):1535-46. PMID: 22193986; PMCID: PMC3718027.
    24. Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet M. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother. 2012 Jul; 61(7):991-1003. PMID: 22127364; PMCID: PMC3719406.
    25. Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet M, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer. 2011 Nov 02; 11:471. PMID: 22044845; PMCID: PMC3217981.
    26. Rodríguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, Martínez-Maza O, Charles AC, Pellegrini M, Helguera G, Penichet M. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma. 2011 Nov; 52(11):2169-78. PMID: 21870996; PMCID: PMC3732792.
    27. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet M. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012 Mar; 1820(3):291-317. PMID: 21851850; PMCID: PMC3500658.
    28. Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet M. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother. 2011 Jul-Aug; 34(6):500-8. PMID: 21654517; PMCID: PMC3717268.
    29. Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. For Immunopathol Dis Therap. 2011 Apr 01; 2(2). PMID: 24286018.
      View in: PubMed
    30. Helguera G, Rodríguez JA, Luria-Pérez R, Henery S, Catterton P, Bregni C, George TC, Martínez-Maza O, Penichet M. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J Immunol Methods. 2011 May 31; 368(1-2):54-63. PMID: 21420412.
      View in: PubMed
    31. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M, Gates M, Patil R, Penichet M, Ljubimov AV, Black KL, Holler E, Ljubimova JY. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res. 2011 Feb 15; 71(4):1454-64. PMID: 21303974; PMCID: PMC3428373.
    32. Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet M, Montano RF. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg. Mol Cancer Ther. 2010 Aug; 9(8):2175-85. PMID: 20682652.
      View in: PubMed
    33. Bermudez-Fajardo A, Stark AK, El-Kadri R, Penichet M, Hölzle K, Wittenbrink MM, Hölzle L, Oviedo-Orta E. The effect of Chlamydophila pneumoniae Major Outer Membrane Protein (MOMP) on macrophage and T cell-mediated immune responses. Immunobiology. 2011 Jan-Feb; 216(1-2):152-63. PMID: 20637522.
      View in: PubMed
    34. Suzuki E, Daniels TR, Helguera G, Penichet M, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol. 2010 May; 36(5):1299-307. PMID: 20372806; PMCID: PMC3732793.
    35. Rodríguez JA, Lopez MA, Thayer MC, Zhao Y, Oberholzer M, Chang DD, Kisalu NK, Penichet M, Helguera G, Bruinsma R, Hill KL, Miao J. Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19322-7. PMID: 19880745; PMCID: PMC2780783.
    36. Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet M, Chen IS. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med. 2009 Aug; 11(8):655-63. PMID: 19455593; PMCID: PMC2834590.
    37. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet M. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009; 11(3):R36. PMID: 19531256; PMCID: PMC2716504.
    38. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet M, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother. 2009 Jun; 58(6):915-30. PMID: 18941743; PMCID: PMC3017872.
    39. Montano RF, Penichet M, Blackall DP, Morrison SL, Chintalacharuvu KR. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents. J Immunol Methods. 2009 Jan 01; 340(1):1-10. PMID: 18848836.
      View in: PubMed
    40. Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet M. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther. 2008 May; 8(5):609-32. PMID: 18407765; PMCID: PMC4535341.
    41. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet M, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol. 2008 May 01; 180(9):6199-210. PMID: 18424742; PMCID: PMC3747671.
    42. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet M, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther. 2008 Mar; 7(3):721-9. PMID: 18347157.
      View in: PubMed
    43. Milioti N, Bermudez-Fajardo A, Penichet M, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol. 2008; 2008:723539. PMID: 18551190; PMCID: PMC2423423.
    44. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet M. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther. 2007 Nov; 6(11):2995-3008. PMID: 18025284.
      View in: PubMed
    45. Rodríguez JA, Helguera G, Daniels TR, Neacato II, López-Valdés HE, Charles AC, Penichet M. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release. 2007 Dec 04; 124(1-2):35-42. PMID: 17884229.
      View in: PubMed
    46. Fujita M, Lee BS, Khazenzon NM, Penichet M, Wawrowsky KA, Patil R, Ding H, Holler E, Black KL, Ljubimova JY. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release. 2007 Oct 08; 122(3):356-63. PMID: 17630012; PMCID: PMC2394675.
    47. Helguera G, Rodríguez JA, Daniels TR, Penichet M. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunol Immunother. 2007 Sep; 56(9):1507-12. PMID: 17310381.
      View in: PubMed
    48. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet M, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007 May 01; 109(9):3915-21. PMID: 17213289; PMCID: PMC1874561.
    49. Daniels TR, Delgado T, Helguera G, Penichet M. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006 Nov; 121(2):159-76. PMID: 16920030.
      View in: PubMed
    50. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet M. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006 Nov; 121(2):144-58. PMID: 16904380.
      View in: PubMed
    51. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet M. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006 Oct 15; 108(8):2745-54. PMID: 16804109; PMCID: PMC1895578.
    52. Helguera G, Rodríguez JA, Penichet M. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther. 2006 Apr; 5(4):1029-40. PMID: 16648575.
      View in: PubMed
    53. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet M. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol. 2006 Feb; 43(6):667-76. PMID: 15908002.
      View in: PubMed
    54. Dela Cruz JS, Morrison SL, Penichet M. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine. 2005 Sep 15; 23(39):4793-803. PMID: 15967544.
      View in: PubMed
    55. Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet M. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine. 2006 Jan 16; 24(3):304-16. PMID: 16125282.
      View in: PubMed
    56. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet M, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther. 2005 Jun; 4(6):956-67. PMID: 15956253.
      View in: PubMed
    57. Helguera G, Penichet M. Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med. 2005; 109:347-74. PMID: 15585931.
      View in: PubMed
    58. Asai T, Trinh R, Ng PP, Penichet M, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng. 2005 Feb; 21(6):145-55. PMID: 15748688.
      View in: PubMed
    59. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet M. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine. 2003 Mar 28; 21(13-14):1317-26. PMID: 12615426.
      View in: PubMed
    60. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet M. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10706-11. PMID: 12149472; PMCID: PMC125019.
    61. Yoo EM, Chintalacharuvu KR, Penichet M, Morrison SL. Myeloma expression systems. J Immunol Methods. 2002 Mar 01; 261(1-2):1-20. PMID: 11861062.
      View in: PubMed